Aditxt, Inc. 8-K

What Happened

• Aditxt, Inc. filed a Form 8-K reporting that Amro Albanna notified the company of his resignation as Chief Executive Officer on May 29, 2026, resigned from the Board on May 30, 2026, and the Board accepted his CEO resignation effective May 31, 2026. The filing states his director resignation was not due to any disagreement with the company.
• The Board appointed Jeffrey M. Busch (age 68) as Interim Chief Executive Officer effective May 31, 2026. Mr. Busch has led Ignite Proteomics LLC (an Aditxt subsidiary) since March 2026, previously founded and led Global Medical REIT Inc. (NYSE: GMRE), and has decades of senior roles in biotech/healthcare; he holds a J.D. from Emory and an M.P.A. and B.S. from NYU.
• Additional leadership changes: Shahrokh Shabahang resigned from the Board effective May 31, 2026 (not due to any disagreement) and remains Aditxt’s Chief Innovation Officer. Rowena Albanna notified the company she will resign as Chief Operating Officer effective June 5, 2026. The company issued a press release on June 1, 2026 announcing these items.

Key Details

• CEO resignation timeline: notification May 29, director resignation May 30, CEO resignation effective May 31, 2026.
• Interim CEO: Jeffrey M. Busch appointed May 31, 2026; age 68; long track record in healthcare/biotech leadership and public company experience.
• Interim pay: Company intends to enter an interim employment arrangement with Mr. Busch providing a $500,000 annual base salary; material terms not finalized and will be reported in an amendment.
• COO departure: Rowena Albanna to resign effective June 5, 2026.

Why It Matters

• Leadership change is material for investors because the CEO and other senior management departures can affect company strategy, operations, and investor confidence. Aditxt has installed an experienced interim CEO with healthcare and public-company experience, which may support continuity during the transition.
• The filing notes no disagreements with management or the company regarding the director resignations, which reduces the likelihood of governance conflict disclosed in this report. Compensation details for the interim CEO are pending and will be disclosed in an amendment, which investors may watch for as an indicator of near-term executive costs.